$323 Million is the total value of SILVERARC CAPITAL MANAGEMENT, LLC's 82 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LVTX | Exit | LAVA Therapeutics NVequities | $0 | – | -140,291 | -100.0% | -0.10% | – |
| CVRX | Exit | Cvrx Incequities | $0 | – | -30,000 | -100.0% | -0.12% | – |
| ABOS | Exit | Acumen Pharmaceuticals Incequities | $0 | – | -146,922 | -100.0% | -0.25% | – |
| Exit | Astria Therapeutics Incequities | $0 | – | -93,823 | -100.0% | -0.52% | – | |
| MCRB | Exit | Seres Therapeutics Incequities | $0 | – | -232,525 | -100.0% | -0.54% | – |
| RXDX | Exit | Prometheus Biosciences Incequities | $0 | – | -13,921 | -100.0% | -0.62% | – |
| ALT | Exit | Altimmune, Inccall | $0 | – | -415,700 | -100.0% | -0.72% | – |
| MDGL | Exit | Madrigal Pharmaceuticals Incequities | $0 | – | -10,000 | -100.0% | -1.00% | – |
| CGEM | Exit | Cullinan Oncology Incequities | $0 | – | -265,032 | -100.0% | -1.12% | – |
| ALNY | Exit | Alnylam Pharmaceuticals Incequities | $0 | – | -14,043 | -100.0% | -1.16% | – |
| ETNB | Exit | 89bio, Inccall | $0 | – | -200,000 | -100.0% | -1.26% | – |
| REGN | Exit | Regeneron Pharmaceuticals Incequities | $0 | – | -5,000 | -100.0% | -1.70% | – |
| IMGN | Exit | ImmunoGen, Inccall | $0 | – | -1,128,200 | -100.0% | -1.79% | – |
| PLRX | Exit | Pliant Therapeutics, Inccall | $0 | – | -199,600 | -100.0% | -2.19% | – |
| BLU | Exit | Bellus Health Incequities | $0 | – | -1,000,000 | -100.0% | -2.97% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- SilverArc Capital, LLC #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTRA-CELLULAR THERAPIES INC | 12 | Q3 2023 | 7.8% |
| IMMUNOGEN INC | 12 | Q3 2023 | 8.3% |
| Morphic Holding Inc | 12 | Q3 2023 | 4.5% |
| UNUM THERAPEUTICS INC | 12 | Q3 2023 | 3.2% |
| INSMED INC | 12 | Q3 2023 | 3.5% |
| UNITED THERAPEUTICS CORP DEL | 12 | Q3 2023 | 2.2% |
| MERUS N V | 11 | Q3 2023 | 5.1% |
| VERACYTE INC | 11 | Q3 2023 | 4.9% |
| EVOGENE LTD | 11 | Q3 2023 | 1.6% |
| COMPUGEN LTD | 11 | Q3 2023 | 1.1% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Benitec Biopharma Inc.Sold out | February 08, 2023 | 0 | 0.0% |
| DELCATH SYSTEMS, INC.Sold out | February 08, 2022 | 0 | 0.0% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G/A | 2023-02-08 |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.